Page 3 - Aaron Lisberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aaron lisberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aaron Lisberg Today - Breaking & Trending Today

Dato-DXd Significantly Improves PFS in Select Subsets of Advanced/Metastatic NSCLC

The Trop-2 directed antibody drug conjugate datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer, however those with squamous histology did not experience a benefit. ....

Los Angeles , United States , Aaron Lisberg , University Of California , Safety Signals , Lung Cancer , Esmo Congress ,

TROPION-Breast01, TROPION-Lung01 Demonstrate PFS Benefit of Datopotamab Deruxtecan in Metastatic Breast Cancer, NSCLC

Datopotamab deruxtecan not only demonstrated a statistically significant improvement over chemotherapy for breast cancer and docetaxel for non–small cell lung cancer (NSCLC), but the intervention therapy had less toxicity. ....

United States , Los Angeles , Aaron Lisberg , Aditya Bardia , Harvard Medical School Aditya Bardia , University Of California , Harvard Medical School , Harvard Medical , Esmo Congress , Datopotamab Deruxtecan , Breast Cancer ,

AstraZeneca : Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial -October 23, 2023 at 10:40 am EDT

Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan demonstrated a statistically significant improvement for the primary endpoint of. ....

Susan Galbraith , Aaron Lisberg , Daiichi Sankyo , Ken Takeshita , European Society For Medical Oncology , Presidential Symposium , European Society , Medical Oncology , Thoracic Medical Oncology , Executive Vice President , Global Head ,

High Translation Costs Hinder Minority Participation in Trials

High Translation Costs Hinder Minority Participation in Trials
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United States , Manavi Hegde , Jacksonp Lind Lebuffe , Michaela Teitell , Mariaj Fernandez Turizo , Maria Garcia Jimenez , Yazeed Radwan , Beth Glenn , Arjan Gower , Amy Cummings , Deboryy Li , Michael Teitell , Tristan Grogan , Aaron Lisberg , Amyl Cummings , Betha Glenn , Edward Garon , Paigem Brodrick , David Elashoff , Mariaa Velez , Maria Velez , Maggie Lindenbaum , Cancer Center , David Geffen School Of Medicine , Jonsson Comprehensive Cancer Center , Therapeutics Program Area ,

Dr Lisberg on Emerging Post-Osimertinib Treatment Options in EGFR-mutant NSCLC

Aaron Lisberg, MD, discusses ongoing and future efforts to expand effective treatment options for patients with osimertinib-resistant, EGFR-mutant non–small cell lung cancer. ....

United States , Aaron Lisberg , Los Angeles , University Of California , Egfr Mutation , Non Small Cell Lung Cancer , Antibody Drug Conjugates , Her3 Dxd , Dato Dxd , Phase 1 Chrysalis 2 Trial ,